Data / Form D filings / Lytica Therapeutics, Inc.
Lytica Therapeutics, Inc.: Form D filings
Lytica Therapeutics, Inc., a biotechnology company in Cambridge, MA, filed 3 Form D notices with the SEC between 2024 and 2025. The latest, on April 11, 2025, reports $6 million sold of an offering with no set size to 17 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 840 MEMORIAL DRIVE, Cambridge, MA, 02139
- Phone
- (617) 475-7374
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2015049
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 11, 2025 | New notice | Indefinite | $6,000,000 | 17 | Feb 28, 2025 | sec.gov | |
| Aug 19, 2024 | New notice | Indefinite | $1,750,000 | 9 | Jul 3, 2024 | sec.gov | |
| Mar 12, 2024 | New notice | Indefinite | $4,065,000 | 14 | Feb 27, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| JEAN-FRANCOIS DUCREST | Director | |
| JAMES LATORRE | Director | |
| DANIEL MACAYA | Director | |
| RIDA MOURTADA | Executive Officer, Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Apr 7, 2025 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Lytica Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.